Shanghai Xianbo Biotechnology

Xianbo Biological is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of next-generation cell therapies. The company focuses on engineering CAR-T and CAR-NK cells to treat hematologic malignancies, solid tumors, and autoimmune diseases. Their core technology includes a universal cell therapy platform and bispecific CAR constructs designed to overcome tumor heterogeneity and improve therapeutic safety. Xianbo's lead candidate, XB001, is a bispecific CAR-T targeting CD19 and CD22 for B-cell malignancies, currently in clinical trials. Backed by prominent investors like Hillhouse and OrbiMed, the company aims to provide more accessible and effective off-the-shelf cell products through its advanced manufacturing capabilities.